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Abstract
In terms of its soluble precursors, the coagulation proteome varies quantitatively among apparently healthy individuals. The
significance of this variability remains obscure, in part because it is the backdrop against which the hemostatic
consequences of more dramatic composition differences are studied. In this study we have defined the consequences of
normal range variation of components of the coagulation proteome by using a mechanism-based computational approach
that translates coagulation factor concentration data into a representation of an individual’s thrombin generation potential.
A novel graphical method is used to integrate standard measures that characterize thrombin generation in both empirical
and computational models (e.g max rate, max level, total thrombin, time to 2 nM thrombin (‘‘clot time’’)) to visualize how
normal range variation in coagulation factors results in unique thrombin generation phenotypes. Unique ensembles of the 8
coagulation factors encompassing the limits of normal range variation were used as initial conditions for the computational
modeling, each ensemble representing ‘‘an individual’’ in a theoretical healthy population. These ‘‘individuals’’ with
unremarkable proteome composition was then compared to actual normal and ‘‘abnormal’’ individuals, i.e. factor
ensembles measured in apparently healthy individuals, actual coagulopathic individuals or artificially constructed factor
ensembles representing individuals with specific factor deficiencies. A sensitivity analysis was performed to rank either
individual factors or all possible pairs of factors in terms of their contribution to the overall distribution of thrombin
generation phenotypes. Key findings of these analyses include: normal range variation of coagulation factors yields
thrombin generation phenotypes indistinguishable from individuals with some, but not all, coagulopathies examined;
coordinate variation of certain pairs of factors within their normal ranges disproportionately results in extreme thrombin
generation phenotypes, implying that measurement of a smaller set of factors may be sufficient to identify individuals with
aberrant thrombin generation potential despite normal coagulation proteome composition.
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Introduction
The coagulation of blood is the initial phase of the biological
repair process that responds to perforating trauma to the
vasculature; its function is to stop blood loss from the circulatory
system by establishing a temporary barrier between the intra- and
extra-vascular compartments. The enzyme thrombin is a central
product of the response to vascular injury, displaying procoagu-
lant, anticoagulant, fibrinolytic and cellular effects; the magnitude
and timing of its effects are critical to normal hemostasis [1].
Relatively unique levels of detail are available for this biological
network concerning its cellular and protein components, connec-
tions between these components, and the dynamics characterizing
their interactions. Because of this, descriptions of this overall
reaction network have been advanced using ensembles of ordinary
differential equations (ODEs) [2,3,4,5,6,7] or more elaborate
mathematical constructs for both closed and flow based model
systems [8,9,10,11,12,13,14,15,16]. Our work has focused on
developing and validating an ODE-based description limited to
the tissue factor (Tf) pathway to thrombin formation [2] and then
using this model in concert with empirical studies to develop
concepts of normal [17] and aberrant thrombin generation in
individuals and populations with chronic or acute pathologies [18]
as well as understanding mechanisms of anticoagulant efficacy
[19,20,21].
An important issue in developing a predictive model of
coagulation with clinical utility is the tension between the
complexity of the model (its relative level of congruence with the
biological network) and the capacity to measure the actual
physiochemical parameters (i.e. initial concentrations of reactants
and rate constants) governing the system. With respect to
comparatively modeling the coagulation systems of individuals in
the human population, the working assumption is that, in the
absence of a specific mutation that alters the function of a key
enzyme or substrate (e.g. factor (f)V Leiden), the rate constants are
invariant. Thus measurement error in rate constants would be the
primary source of uncertainty in their values [22]. In contrast, the
concept of initial species levels is complicated by issues beyond
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reasonable assessment methods concerning the in vivo concentra-
tions (or surface level expression) of cellular components of the
coagulation proteome and the fact that individuals are known to
vary in concentrations of soluble coagulation factor precursors. A
reasonable resolution of the conflict between model complexity
and required input data is a precondition if one is aiming to
develop a model that provides therapeutic guidance on an
individual basis.
Our approach for modeling individuals has generally been to
limit the description of the network to seven circulating precursor
proteins (factors II, V, VII, VIIa, VIII, IX, X) and two inhibitors
(antithrombin (AT), and tissue factor pathway inhibitor (TFPI)).
The rationale for this has four parts: 1) The magnitude of the
normal range variation of these soluble proteins between
individuals is greater than the measurement uncertainty for these
proteins, a methodologic precondition for their use to discriminate
among individuals; 2) These proteins appear to be central to the
process of Tf initiated thrombin formation [23] and its regulation
by anticoagulant agents. Absolute deficiencies in any of these are
either incompatible with life [24], or result in bleeding disorders
(fV, fX, prothombin, fVIII, fIX or thrombosis (AT) [24,25].
Additionally, the importance of the four vitamin K dependent
(VKD) proteins (fII, fVII/fVIIa, fIX and fX) to normal
hemorrhage control is exemplified by their status as primary
targets for the anticoagulants warfarin [26] and unfractionated
heparin (UFH) [27], both of which have been used for over 60
years. These two therapeutic agents mirror each other in the scope
of their action, since UFH potentiates the inhibition of all of the
procoagulant enzymes that warfarin anticoagulation targets
indirectly by suppressing the levels of their functional precursors;
3) The mathematical representation of the interactions of these
proteins in the reaction network appears valid, based on the
congruence between empirical reconstructions of this limited
network and model descriptions [2,20]; and 4) Availability of
populations with the necessary composition data. Even with the
small subset of factors we used in this model, databases containing
these 8 measured values for individuals are scarce.
In this study, we systematically perturb, within the acceptable
healthy clinical laboratory range, the initial protein concentrations
in our ODE based model of Tf-initiated blood coagulation to
evaluate the effect on thrombin generation. A unique graphical
method is developed to integrate standard measures used to
characterize thrombin generation in empirical and computational
models (e.g max rate, max level, total thrombin, time to 2 nM
thrombin: ‘‘clot time’’) to visualize how normal range variation in
coagulation factors results in unique thrombin generation
phenotypes. Three approaches are taken: 1) characterizing the
possible range of thrombin generation phenotypes as a function of
normal range variation in factor levels, i.e. defining the theoretical
population range of the healthy coagulant response to Tf; 2)
relating the thrombin generation profiles of apparently healthy
and hemostatically challenged populations derived using their
actual plasma coagulation factor composition to the theoretical
‘‘normal’’ population range; and 3) systematically analyzing the
sensitivity of model output of all species collectively and of
thrombin specifically to normal range variation in each coagula-
tion factor.
Key findings of these analyses include that normal range
variation of coagulation factors yields thrombin generation
phenotypes indistinguishable from individuals with some but not
all coagulopathies and that coordinate variation of certain pairs of
factors disproportionately results in extreme thrombin generation
phenotypes, implying that measurement of a smaller set of factors
may be sufficient to identify individuals with aberrant thrombin
generation potential. These novel types of analyses can ultimately
be used to develop clinical tools to evaluate individual procoag-
ulant potential.
Materials and Methods
Ethics
Participation of both the individuals undergoing warfarin
therapy and the apparently healthy control individuals was
approved by the Jagiellonian University Ethical Committee. All
participants gave informed written consent.
Participation of severe hemophilia A individuals was approved
by the Institutional Review Board at the Centre Hospitalier
Universitaire Sainte-Justine Montre ´al Quebec and approved by
the University of Vermont Human Studies Committee. Informed
written consent was obtained from all individuals.
Mathematical Model
The current mathematical model of coagulation utilizes
reactions described in publications by Hockin et al. [2] and
Butenas et al. [28] describing the dynamics of tissue factor (Tf)
initiated blood coagulation. Inputs to the model include the
concentrations of procoagulant factors II, V, VII/VIIa, VIII, IX,
X and the anticoagulants TFPI and AT and the rate constants
derived from experimental measurements made under conditions
of saturating concentrations of phospholipids [2]. The starting
concentration of fVIIa was always 1% of the starting fVII
concentration. MatLabs stiff solver ode15 s [29] was used to
integrate the ODE model with variable time steps whose
maximum size was set to 5610
23 s. The model is initiated by
exposing the inputs to 5 pM Tf and yields concentration versus
time profiles for all of the 34 species representing reactants,
intermediates or products (Table S1).
Populations
Thirty-two apparently healthy individuals recruited from
hospital and university staff (Jagiellonian University Medical
College, Krakow, Poland) served as controls. Warfarin treated
individuals (N=65; 23 females, 42 males; age: 25–75 years) were
apparently on stable anticoagulation (mean time of 4 months;
2#INR#3.3). Indications for vitamin K antagonist administration
were atrial fibrillation (N=26), venous thromboembolism (N=25)
or aortic prosthetic valve implantation (N=14). The exclusion
criteria were recent (preceding 6 months) thromboembolic event,
acute infection, liver injury, renal insufficiency, autoimmune
disorders or known cancer. Three individuals had a thrombotic
event subsequent to the blood draw for compositional analysis.
Severe hemophilia A individuals (by diagnosis; N=16) displayed
fVIII levels ranging from not detectable to #1% at the time of the
blood draw used for compositional analysis.
Modeling thrombin generation in individuals
Thrombin generation phenotypes. In empirical models,
thrombin is the most common analyte both because of its ease of
measurement and its central and diverse roles [1]. Thrombin
generation in these closed model systems displays three distinct
phases: initiation of coagulation, propagation of a-thrombin
formation, and termination of the procoagulant response (Figure 1).
Computationally simulated thrombin generation profiles (cTGPs)
were evaluated by standard summary measures that described
each curve including the maximum level and rate of thrombin
generation, total thrombin generated (the area under the curve)
and the time to 2 nM a-thrombin, which corresponds to clot time
Normal and Abnormal Thrombin Generation
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used to define a thrombin generation phenotype.
Thrombin generation in a hypothetical normal
population. To produce a representation of the distribution of
possible thrombin generation phenotypes, the eight factors with
non- zero initial concentrations were varied across their normal
range. This population of factor ensembles was produced by
allowing each factor to have three possible normal range values:
extreme low, mean physiologic (factors at 100%) and extreme high
(Table S2), yielding (3
8) permutations. From each of these cTGPs
the four thrombin parameters were extracted.
Thrombin generation in actual populations. Thrombin
generation using actual plasma factor composition data from an
apparent healthy population (N=32), a severe hemophilia A
population (N=16), and a warfarin treated group (N=65) was
simulated and the 4 thrombin parameters extracted for each
person in each group. The mean factor levels for each population
are presented in Table S3. All factor levels in these populations are
within their normal ranges, with the exception of fVIII in the
hemophiliac population, and the vitamin K dependent proteins in
the individuals undergoing warfarin therapy.
Thrombin generation in a hypothetical abnormal
population. To produce populations characterized by fIX
deficiency, prothrombin deficiency and AT deficiency, the
plasma composition data from the apparently healthy population
(N=32) was altered as follows: each individual’s fIX level set to
0.01% mean physiologic; or each individual’s PT concentration set
to 10% (severe PT deficiency) or 40% mean physiologic; or each
individual’s AT concentration set to 40% (heterozygous AT
deficiency) mean physiologic. In each instance, all other factor
concentrations were left at their individual measured values.
Model sensitivity to normal range variation in factor
levels
Analysis of single factor dependence. To characterize the
impact of normal range variation in factor levels on model output
of all species, all species with non-zero values at time zero except
Tf (8 independent species in total: fII, fV, fVII/VIIa, fVIII, fIX,
fX, TFPI, AT) were altered, one at a time, in eleven evenly spaced
intervals between the low normal and high normal value for that
factor and time course profiles for all 34 species collected. The
clinically accepted normal range values were obtained from
Fletcher Allen Health Care (Burlington, VT; Table S2). For each
of the 8 factors, the collection of cTGPs derived from the 11 initial
factor concentrations for a given output species is referred to as the
ensemble range for that species with respect to that factor (272
ensembles in total), with the profile reflecting all factors at one
hundred percent their mean physiologic value defined as the
standard profile for that species.
Ensemble standard deviation. In order to evaluate the
impact of normal range variation in each factor (g) on model
output of each species, we utilized a modification of our previously
described approach for analyzing our model’s sensitivity to
perturbations in its rate constants [22]. For any given model
output species (f) at any selected time (t) an ensemble standard
deviation (sf
g(t)) can be calculated. It is designed to represent the
variation in that species concentration at time t that occurs as a
result of variation in the initial concentration of factor g when all
other factors are held at their mean physiologic values. A group of
predicted time courses (11 time courses) for species ( f ) generated
by varying the initial concentration of factor g in linearly spaced
intervals across its normal range provides the data set from which
the ensemble standard deviation is calculated at 1 second intervals
over the 1200 s time course (Figure S1 A & B).
Coefficient of variation. The impact of variation in reaction
concentration of the each of the 8 initially nonzero factors (g)o n
the production of any model species ( f ) was normalized using a
coefficient of variation (wf
g(t)) defined to be the ensemble standard
deviation at each time t expressed as a fraction of the peak value
(P(f)) of that species when all factors are initially at 100% of their
mean physiologic value (standard model curve). For example,
thrombin (IIa) response to normal range variation in TFPI is given
by wIIa
TFPI(t)=
sIIa
TFPI(t)
272nM
, where 272 nM thrombin is the peak
concentration of thrombin under standard conditions (see
Figure 1). Normalization was performed in order to avoid
numerical effects related to the differences in concentrations
(.10
6) between species in the pathway. The peak concentration
(P(f)) was chosen rather than the corresponding concentration at
time t from the standard model curve or the ensemble mean curve
because these are both time-dependent (Figure S1C).
Time averaged coefficients of variation for thrombin. For
each of the 8 non-zero initial factors (g), the coefficients of variation
(wIIa
g (t)) were averaged over the 1200 s time course to yield 8 time
averaged coefficients of variation for thrombin (Figure S1C). These 8
values were summed, each individual value expressed as a fraction of
that sum, and then ranked by the magnitude of its contribution to the
total variation in thrombin induced by normal range variation of the
8f a c t o r s .
Time averaged coefficients of variation for all model
species. For each non-zero factor (g) at time (t), the mean
coefficient of variation for all resulting protein species is given
bycg(t)~
1
34
X34
f~1 wf
g(t). The time average of cg(t) for factor (g)
over the 20 minutes of the simulation is denoted by Cg. The 8 Cg
values were summed, each expressed as a fraction of the total, and
then ranked by the magnitude of their contribution.
Analysis of pair wise variation in factor levels on
thrombin generation. Each pair of factors (28 possible) was
varied together with the same 11 linearly spaced values within
their individual normal ranges, leaving the other 6 factors at their
mean physiologic value. This resulted in 121 cTGPs for each
factor pair from which the four thrombin parameters were
extracted. The range in each of the four parameters induced by
Figure 1. Thrombin generation profile reflecting the dynamics
observed in a closed model system. A computationally-simulated
time course of thrombin generation with all factors at their mean
physiologic level and a 5 pM tissue factor stimulus is shown. Also
indicated are the thrombin parameters (time to 2 nM thrombin (clot-
time), total thrombin, maximum thrombin, maximum rate) used in this
analysis.
doi:10.1371/journal.pone.0030385.g001
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range values expressed as a fraction of the largest perturbation in
that parameter observed among the 28 factor pairs. For example
coupled variations in AT and TFPI yielded the largest range in the
time to 2 nM active thrombin values (a 5 min range between 3
and 8 min) and thus all 27 other ranges for this thrombin
parameter are ratioed to this range value.
Results
The normal range variation in plasma concentration that
characterizes the 8 model species with initial non-zero values is
presented in Table S2. In order to assess the consequences of this
variation, computationally simulated thrombin generation profiles
(cTGPs) were produced by assigning a specific normal range value
to each of these factors and a constant concentration (5 pM) for
tissue factor. In this analysis, the term ‘‘individual’’ refers to a
unique ensemble of these 8 factors from which a cTGP,
representing the model integrated effect of this ensemble, is
generated. The ensemble having all factors at their mean
physiologic level serves as a reference cTGP for assessing the
relative intensity of thrombin generation characterizing other
ensembles. To capture the maximum potential distribution (scope)
of cTGPs resulting from normal range variation in these factors, a
theoretical population of ‘‘normal’’ individuals, each with a unique
ensemble of initial factor concentrations, was generated by
allowing each factor to have 3 possible values spanning its normal
range (3
8 or 6561 individuals). To quantify differences between
these cTGPs, thrombin parameters were extracted from each
cTGP (see Figure 1).
Factor composition and thrombin generation
phenotypes
Figure 2 presents cTGPs of groups of individuals in the
theoretical population selected because their cTGPs showed
significant overlap despite their disparate factor composition.
Factor ensembles (presented in the figure insets) with ,50% or
greater differences in 4 to 8 factor concentrations characterize
these individuals. Such individuals, representing disparate factor
ensembles but with similar cTGPs, are defined to have the same
thrombin generation phenotype. Thus three thrombin generation
phenotypes are represented in Figure 2.
In panel A, individuals with cTGPs that overlap the reference
cTGP are shown. Panels B and C show individuals with similarly
disparate factor composition but overlapping cTGPs that display
more or less robust thrombin generation respectively. In panel B,
normal range factor variation produces ensembles resulting in
cTGPs displaying a 2–3 fold shortening of the clot time parameter
and 2 to 3 fold increases in the parameters max rate, max level and
total thrombin compared to the reference cTGP. Panel C displays
distinct ensembles that produce overlapping cTGPs characterized
by a relatively attenuated response: a 2–3 fold prolongation of the
clot time parameter and 2 to 3 fold decreases in the parameters
max rate, max level and total thrombin compared to the reference
cTGP.
The results of these limited comparisons highlight a conse-
quence of normal range variation in factor levels on thrombin
generation: factor variation per se (analyzing factor concentrations
and not their integrated effect) is not a sufficient discriminator for
predicting differences in thrombin generation between individuals.
Ensembles, when integrated mechanistically, can effectively
compensate for apparently procoagulant or anticoagulant varia-
tions in individual factor levels [18], yielding similar thrombin
outputs.
The possible range of ‘‘normal’’ thrombin generation
phenotypes
Figure 3 compares all individuals in the theoretical population
in terms of their relative ability to generate thrombin by creating a
graphic representation of each individual that reflects the
magnitude their thrombin parameters. Individuals (model inte-
grated factor ensembles) are depicted by a positioned, colored ball
of specific size, a collective representation of the four thrombin
parameters extracted from their respective cTGPs. Time to clot (y
axis) and max rate parameters (x axis) position each individual,
while color indicates the max level and size defines the total
thrombin parameter. To relate the differences between cTGPs
observed in Figure 2 to this form of presentation, three individuals
are highlighted: an individual with all factors at mean physiologic
concentrations and individuals from Figures 2B and 2C. The levels
of variation for the thrombin parameters in this population are as
follows: 6.5 fold for the clot time (2.3 to 14.97 min); 33.4 fold for
max level (23.7 to 792.4 nM); 120 fold for max rate (0.1 to
12.4 nM/s); and 17 fold for total thrombin (8,179 to
134,338 nMNs) (see Table S4). Thrombin parameters for the
individual with all factors at mean physiologic values are: clot
time—4.4 min; max rate—2.21 nM/s; max level—271.4 nM;
and total thrombin—56,458 nMNs.
This population is designed to set the outer boundaries for the
types of thrombin generation phenotypes possible because of
normal range variations in coagulation factor levels. As is evident
from Figure 2 and visual inspection of Figure 3, significant overlap
of individuals occurs, and thus the number of thrombin generation
phenotypes is less than the number of individuals (factor
ensembles). The question that presents itself is whether all
potential phenotypes derived from ensembles with normal factor
levels are representative of a normal or healthy hemostatic
response?
Normal thrombin generation phenotypes; possible range
vs actual
Computationally analyzed thrombin generation using factor
composition data from an apparently healthy control group of 473
individuals from the Leiden Thrombophilia Study has been
reported [17]. Factor level variation in this population was similar
to or exceeded the ranges used to generate the theoretical
population presented in Figure 3 (Table S2). In this population of
Dutch individuals (272 women, 201 men) the range in thrombin
parameters was: 3.3 fold for the clot time; 3.9 fold for maximum
level thrombin; 4.8 fold for maximum rate; and 4.5 fold for total
thrombin. The 2 to 20 fold larger ranges predicted for the
thrombin parameters of the theoretical population reflect factor
ensembles that were possible in the LETS population (given the
factor composition ranges) but that did not occur.
The wider ranges of thrombin parameters characterizing the
theoretical population have two potential origins: a methodologic
one due to its larger size, emphasis on the extremes of each factor
range and its treatment of all possible ensembles as of equal
probability; or a biological one reflecting the fact that some
ensembles, perhaps those resulting in individuals with the more
extreme characteristics in Figure 3, are consistent with coagulo-
pathic states and thus would not be found in a healthy population.
Relevant coagulation factor composition data from comparably
sized populations of apparently healthy individuals are not
available currently. However, factor composition data for smaller
populations, including those with coagulopathies resulting from
inherited or pharmacologically induced deficiency states, are
available. A comparative analysis of individuals with defined,
Normal and Abnormal Thrombin Generation
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coagulant response was performed to determine whether their
thrombin generation phenotypes fall within the theoretical normal
range population distribution.
Figure 4 presents the graphic representation of the thrombin
parameters characterizing a population of apparently healthy
individuals (N=32), with the boundary of the theoretical
population (from Figure 3) also shown. Factor level variation in
this population is presented in Table S2 and the mean factor levels
in Table S3. The max level and max rate parameters vary ,3 fold
in this population, the total thrombin parameter ,4 fold and the
clot time parameter ,1.4 fold. The parameter ranges for max
level, max rate and total thrombin are similar to those reported for
the larger LETS population (N=473) [17] while the range of clot
time values in this population is ,40% that of LETS. Thus both
populations appear confined to a relatively small region of the
potential distribution of thrombin generation phenotypes available
because of normal range variation in coagulation factor levels.
‘‘Abnormal’’ thrombin generation phenotypes
Figure 5 presents a comparison of thrombin generation between
a group of severe hemophilia A individuals (N=16; factor
VIII,1%; panel A), a cohort of individuals anticoagulated with
warfarin (N=65; panel B) and the relevant subset of the
theoretical population (panel C). Plasma composition data for
the hemophilia and warfarin treated populations are presented in
Table S3. To facilitate the comparison, the max rate (x axis)
parameter extends only to 1.5 nM/s and the size of each
individual’s symbol (total thrombin parameter) has been increased
by a factor of 5 relative to Figure 3 to improve its visibility. The
Figure 2. Thrombin generation time courses from selected individuals from an hypothetical population defined by normal range
variation in factors. Individuals were selected with disparate factor composition, but similar thrombin generation profiles and compared to an
individual (control) with all factor levels at their mean physiologic value. Insets detail factor composition (as percentage of mean physiologic) which is
variable among these individuals, with all other factors that are not listed at mean physiologic values. Panel A: 4 individuals similar to the control
profile; Panel B: 4 individuals with accelerated and more robust thrombin generation relative to the control; and Panel C: 4 individuals with
suppressed and delayed thrombin generation relative to the control.
doi:10.1371/journal.pone.0030385.g002
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indicated in panel C.
In general, individuals with severe hemophilia A, in the absence
of replacement therapy with rfVIII or other agents, experience
prolonged and potentially life threatening bleeding in response to a
hemostatic challenge as well as episodes of ‘‘spontaneous bleeding’’
[30]. In this hemophilia population, all factors other than fVIII are
within the normal range (Table S3).FVIII concentrationsvary from
0.07% to 1% mean physiologic. For the overall population the
parameter ranges were: time to 2 nM thrombin—y axis, range
(8.2R14 min); maximum rate of thrombin generation—x axis,
range (0.02R97 nM/s); maximum thrombin level—color, range
(16R50 nM); and total thrombin—size, range (17,300R40,845
secNnM).
As can be seen by comparing the distribution of phenotypes in
panel C with that of panel A, the hemophilia population is
positioned outside the most extreme phenotypes in the theoretical
normal population. These individuals are characterized by lower
max rates but substantially higher total thrombin values across
their distribution than their nearest neighbors in the theoretical
population. The defect in thrombin generation occasioned by
severe fVIII deficiency also segregates these individuals from the
warfarin-treated group, again drive by differences in max rate and
total thrombin parameters.
The warfarin-treated individuals represented in Figure 5B, were
initially considered, in terms of their clinical history, to be stably
anticoagulated, as assessed by a 2 to 3 fold prolongation of their
plasma clotting time in a standardized assay (INR: 2 to 3.3). In this
population, the non-VKD protein concentrations are all within the
normal range, while the VKD proteins (fII, fX, fIX, fVII/fVIIa) are
suppressed 50 to 90%, with the level of suppression of each VKD
protein varying between individuals. For the overall population
the parameter ranges were: time to 2 nM thrombin, range
(5.3R17 min); maximum rate of thrombin generation, range
(0.08R1 nM/s); maximum thrombin level, range (13R100 nM);
and total thrombin, range (6,048R18,978 secNnM).
The 65 individuals of the warfarin-treated population distribute
within the region of the theoretical population characterized by
low max rates and prolonged clot times (Figure 5A). This is
demonstrated more clearly in Figure 5C, where the boundaries of
the warfarin treated population are indicated by the orange line.
Their overall characteristics, i.e. their 4 thrombin parameters, do
not distinguish them from their nearest neighbors in the theoretical
population, suggesting that this region of the theoretical
population is characterized by thrombin generation phenotypes
reflecting a compromised coagulant response.
Three of the warfarin-treated individuals (circled in Figure 5B)
were subsequently reported to have suffered a thrombotic event.
The graphical method employed separates these individuals from
the remainder of the warfarin-treated group, primarily because of
their max rate parameter, consistent with the idea that they were
under anticoagulated despite clinical INR values between 2.1 and
2.5. Inspection of the plasma factor composition data for these
three individuals shows at most minor differences between their
VKD protein levels (fII 3063%; fVII 3566%; fIX 4262%; fX
32613%; mean6SD) and the overall warfarin-treated population
(Table S3); however, within the non VKD proteins, their TFPI
values (7463%, mean6SD) are at the low end of the range
characterizing this population while their fVIII values (21267%,
mean6SD) are at the high end (Table S3). These compositional
Figure 3. Thrombin generation phenotypes in an hypothetical
population defined by normal range variation in factor levels.
Each individual in the population (6,561) is defined by 4 thrombin
parameters and their phenotype represented graphically by a
positioned colored circle: y axis—time to 2 nM thrombin, range
(2.3R15 min); x axis—maximum rate of thrombin generation, range
(0.1R12.4 nM/s); color—maximum thrombin level, range (23 (dark
blue)R792 nM(brown)); and size—total thrombin, range
(8,179NR134,340 secNnM #). Inset: An individual with all factors at
their mean physiologic value is depicted, the arrow indicating that
individual’s position in the population. Similarly, representative
individuals from Figure 2 panels B and C are included.
doi:10.1371/journal.pone.0030385.g003
Figure 4. Thrombin generation phenotypes in a population of
apparently healthy individuals. Plasma factor composition for 32
individuals was used to generate time courses of thrombin generation,
thrombin parameters were extracted and each individual represented
as described in the legend to Figure 3. The boundaries (magenta) of the
theoretical population are outlined and an individual with all factors at
their mean physiologic values is also presented. Arroe indicates an
individual with all factors at mean physiological.
doi:10.1371/journal.pone.0030385.g004
Normal and Abnormal Thrombin Generation
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30385data are consistent with the graphical characterization of these
individuals as being under anticoagulated compared to the whole
group in two ways: the pattern of high fVIII and low TFPI levels is
computationally consistent with more robust thrombin generation;
and the prothrombin time assay, which is the basis for INR metric,
is relatively insensitive to variations in TFPI and FVIII levels and
thus would not identify these individuals as insufficiently
anticoagulated.
To further test the ‘‘normalcy’’ of our theoretical population of
thrombin phenotypes, additional populations representing ‘‘bleed-
ing’’ phenotypes (fIX deficiency, prothrombin deficiency) or
prothrombotic phenotypes (antithrombin deficiency) were ana-
lyzed. These populations were generated using the group (N=32)
of apparently healthy individuals for which factor composition
data was available (Tables S2 & S3). In each case, all factors were
left at their individual specific values except fIX or prothrombin or
antithrombin, which were set to an average value characterizing
their clinical deficiency state.
Figure 6A presents the distributions of the individuals in the
artificial fIX and prothrombin deficient groups. The outer
boundaries of the theoretical population are depicted by the
yellow line, with each group representing a one factor deficiency
state circumscribed to define its limits. As with Figure 5, the size of
each individual’s symbol (total thrombin parameter) has been
increased by a factor of five to improve its visibility and the x axis
is truncated relative to Figure 3.
The fIX deficient population was modeled to represent a severe
hemophilia B state, with fIX levels set to 0.01%. In general the
bleeding problems associated with severe fIX deficiency (fIX,1%)
are similar to those characterizing hemophilia A [31]. The
distribution of this artificial hemophilia B population lies outside
the hypothetical population and appears roughly equivalent to the
one characterizing actual hemophilia individuals (Figure 5A).
Differences in the total thrombin parameter between the actual
hemophilia A individuals (Figure 5A) and the artificial fIX
deficient individuals reflect the fact that most of the hemophilia
A individuals have higher fVIII levels than the fIX level selected
for the ‘‘hemophilia B’’ population.
Two levels of prothrombin deficiency are also represented in
Figure 6A, with the prothrombin concentration set to 10% or 40%
of its mean physiologic value in each of the 32 control individuals.
Clinically, prothrombin deficiency is a rare coagulation disorder
with homozygous individuals displaying prothrombin levels less
than 10% mean physiologic; it is characterized by severe, often life
threatening bleeding episodes [32]. Heterozygous individuals with
prothombin levels 40 to 60% mean physiologic are usually
asymptomatic, with excess bleeding occurring occasionally after
surgical procedures.
The model representation of homozygous prothrombin defi-
ciency (Figure 6A) places these individuals along the edge of the
theoretical population, overlapping, with respect to three of the
thrombin parameters, the more highly anticoagulated individuals
in the warfarin population (Figure 5B). However, the total
thrombin parameter for individuals with this level of PT deficiency
is suppressed relative to the total thrombin values typifying the
nearest neighbors in the theoretical population and the warfarin-
treated population. The distinction between stably anticoagulated
individuals on warfarin and severe prothombin deficiency is
consistent with the more extreme hemorrhagic phenotype seen in
severe prothrombin deficiency.
In contrast, thrombin parameter analysis of individuals modeled
to be heterozygous in their prothombin deficiency (40% mean
physiologic, Figure 6A) indicates that this population is embedded
within the boundaries of the theoretical population. An individual
from Figure 2C is also graphed to provide a comparison to a
conventional representation of thrombin generation for this region
of the theoretical population. Neither max level nor total thrombin
parameters distinguish these individuals from their nearest
neighbor in the theoretical population. If one excludes the three
warfarin-treated individuals who proved to be insufficiently
Figure 5. Thrombin generation phenotypes in hemophilia A individuals and individuals undergoing warfarin therapy. Plasma factor
composition was used to generate time courses of thrombin generation, thrombin parameters extracted and each individual represented as
described in the Figure 3 legend. The x axis (max rate) is truncated (0–1.5 nM/s) and the size of each individual symbol (total thrombin parameter) has
been increased by a factor of 5 relative to Figure 3 to improve visibility. Also indicated (arrow) is an individual shown in Figure 2C and Figure 3. Panel
A: 16 individuals with severe hemophilia A (fVIII: 0.07% to 1% mean physiologic). Panel B: 65 individuals stablely anticoagulated with warfarin (INR
values between 2 and 3.3). The three individuals who subsequently had a thrombotic event are circled in yellow. Panel C: region of the hypothetical
population distribution displaying the most similar thrombin generation parameters; the boundaries of the distributions of the hemophilia (green)
and warfarin populations (orange+yellow (3 individuals)).
doi:10.1371/journal.pone.0030385.g005
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treated population, displaying shorter clot times and larger max
rates, parameter differences consistent with their overall lack of
bleeding incidents. An individual from Figure 2C is also graphed
to provide a comparison to a conventional representation of
thrombin generation for this region of the theoretical population.
Heterozygous AT deficiency, with an incidence rate of 1 in 500
to 1 in 5000 in the general population, is characterized by AT
concentrations 40 to 60% mean physiologic, below the normal
range variation of ,80 to 170% mean physiologic [33](Table S2).
These lower levels of AT induce a prothrombotic phenotype
associated with a 5 to 50 fold increased risk for venous embolism
[34].
The results of altering AT levels in the 32 control individuals to
40% mean physiologic are presented in Figure 6B. The scaling is
the same as the theoretical population displayed in Figure 3. As
can be seen by visual inspection of Figures 3 and 6B, this level of
AT deficiency yields individuals with extreme thrombin genera-
tion phenotypes with respect to the parameters max level and total
thrombin. Comparison with the model representation (Figure 4) of
the same individuals prior to the induction of AT deficiency also
shows a systematic increase (,2 fold) in the max rate parameter.
None of the nearest neighbors in the theoretical population
(Figure 3) display similar max level and total thrombin parameters.
In fact, no individual in the theoretical population displays total
thrombin levels of the magnitude characterizing the AT deficient
population. The mean total thrombin parameter in the AT
deficient group (392,776 nMNs) exceeds that of the matching 32
controls (71,000 nMNs) by ,5.5 fold.
Single factor contribution to overall variation in thrombin
generation
Table 1 presents the results of an analysis testing the sensitivity
of model outputs to normal range variation in the 8 initial nonzero
factor levels. Each factor was set sequentially to 11 values spanning
its normal range, the other 7 factors held at their mean physiologic
values and the time courses for all 34 model output species
collected. Analysis (Figure S2) resulted in the generation of time
averaged coefficients of variation for all 34 output species which
were manipulated ultimately to rank each factor by the magnitude
of the contribution its normal range variation makes to variation in
all model species or variation in thrombin generation (Figure S3).
It is this ranking, the explained variance, which is presented in
Table 1.
These analyses indicate that two factors account for ,50% of
the observed sensitivity of model output, whether the generation of
Figure 6. Thrombin generation phenotypes for hypothetical fIX deficiency, fII deficiency and AT deficiency. Plasma factor composition
for each of 32 apparently healthy individuals was altered in one factor to reflect each deficiency state, time courses of thrombin generation analyzed
for thrombin parameters and each individual represented as described in the Figure 3 legend. Panel A: severe fIX deficiency (fIX=0.01% mean
physiologic); severe fII deficiency (fII=10% mean physiologic); heterozygous fII deficiency (fII=40% mean physiologic). The x axis (max rate) is
truncated (0–1.5 nM/s) and the size of each individual symbol (total thrombin parameter) has been increased by a factor of 5 relative to Figure 3 to
improve visibility. Also included is the reference individual from Figure 2C. Panel B: heterozygous AT deficiency (AT=40% mean physiologic). Note
that x axis shows the full range depicted in Figures 3 and 4. An individual with all factors at mean physiologic is shown along with an individual in
Figure 2B and Figure 3. The boundaries of the hypothetical population are also shown in Panel A.
doi:10.1371/journal.pone.0030385.g006
Table 1. Ranking factors by the effect that normal range
variation in their initial values has on model output.
A. B.
Rank Factor IIa Exp Var Factor All Factors Exp Var
1 TFPI 32.0 TFPI 30.9
2 II 16.5 VIII 18.2
3 VIII 14.6 AT 12.0
4 AT 12.5 IX 12.0
5 IX 10.8 X 10.7
6 X 5.1 II 7.4
7 V 4.3 V 5.1
8 VII 4.0 VII 3.7
Panel A: The explained variance is defined as the time averaged coefficient of
variation for thrombin for a given factor expressed as a fraction of the sum of all
the time averaged coefficients of variation for thrombin for the 8 factors. Panel
B: For a given factor, the effect of varying its level across its normal range on all
model species is defined as the mean of the time averaged coefficient of
variations for all 34 species. The explained variance is then defined as fraction of
the sum of the mean time averaged coefficients of variation for the 8 factors
(Figures S2 and S3).
doi:10.1371/journal.pone.0030385.t001
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in the initial TFPI concentration has the greatest impact on both
outputs while variation in the fII level is the second most effective
contributor to overall differences in thrombin generation. In
general this analysis suggests that TFPI alone or coordinated
normal range variation of a few factors may account for the
extreme thrombin generation phenotypes in the ‘‘normal’’
theoretical population.
Factor pair induced variation in thrombin parameters
To further explore the relationship between outlying thrombin
generation phenotypes and initial factor composition, a compar-
ison focusing on the effect of normal range variation of pairs of
factors was conducted. The effects of factor pair variation were
quantified in terms of the magnitude of the range of potential
thrombin parameter values induced by the coordinated variation
in the concentrations of each pair of factors. Unlike the sensitivity
analysis ranking the global effects of single factor variation
(Table 1), this approach quantifies the effects of variation on each
thrombin parameter, facilitating direct comparisons to the
distributions of individuals observed in graphical representations
of the various populations.
Figure 7 presents the results of this analysis, with the color scale
reflecting the normalized range values. Each thrombin parameter
box displays 64 range comparisons as colored squares: 28 factor
pair effects are ranked (in duplicate); and the intensity of each
single factor (8 total) contribution to variation in the indicated
thrombin parameter is represented in the reverse diagonal: bottom
right to upper left. Table 2 presents a summary of the most potent
single and factor pair contributors to variation in each thrombin
parameter.
Visual inspection of Figure 7 highlights the differences between
each thrombin parameter’s sensitivity to every single factor and
factor pair induced variation. Maximum parameter ranges
induced by single factor variation are approximately half that
induced by the most effective pair for each parameter. Variations
Figure 7. Factor pair induced variation in thrombin parameters. Pairs of factors (28 possible) were varied through their normal range,
thrombin parameters were extracted from resulting cTGPs, the factor pair induced ranges for each thrombin parameter established, and then the set
of 28 ranges for each thrombin parameter expressed as a function of the largest induced range for that parameter. The color scale reflects the
normalized range values. Each parameter box (64 normalized range values) shows the 28 factor pair effects (in duplicate) and the relative intensity of
each single factor (8 total) contribution to variation in the indicated thrombin parameter (see reverse diagonal: bottom right to upper left).
doi:10.1371/journal.pone.0030385.g007
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coordinate variation of AT and TFPI and AT and fII respectively,
with more than one half the other factors pairs showing relatively
minimal effects (,20% of the most effective pair). In contrast, the
analysis shows the parameters max rate and max level to have a
more complex dependency: strong sensitivity (induced ranges at
least 80% of that for the most effective pair) is observed with
coordinate variation in 8 factor pairs for the max rate parameter
and for 6 factor pairs with the max level parameter.
Discussion
The concentrations of the components of the coagulation
proteome of blood, as measured by standard laboratory tests, vary
among apparently healthy individuals, often ranging 640% to
50% of the mean population value (e.g. Table S2). The significance
of this variation remains relatively unexplored in part because the
imposition of the category of ‘‘healthy’’ implies these differences
are background noise and have no hemostatic consequence.
In this study we have attempted to define the consequences of
normal range variation of components of the coagulation
proteome by using a mechanism based computational approach
that translates coagulation factor concentration data into a
representation of an individual’s thrombin generation potential.
Unique ensembles of the 8 coagulation factors used as initial
conditions for the computational modeling were taken to represent
individuals in a theoretical healthy population and then compared
to normal and ‘‘abnormal’’ individuals, i.e. factor ensembles
measured in apparently healthy individuals, actual coagulopathic
individuals or artificially constructed factor ensembles representing
individuals with specific factor deficiencies. A sensitivity analysis
was then performed to rank either individual factors or all possible
pairs of factors in terms of their contribution to the overall
distribution of thrombin generation phenotypes.
Although limited by its size, the analysis of actual healthy
individuals tentatively indicates that the actual normal distribution
is constrained to a fraction of the theoretical range of ‘‘normal’’
phenotypes. Comparison of the theoretical population to individ-
uals with a hemorrhagic phenotype shows that normal range
variation cannot generate low thrombin generation phenotypes as
extreme as those seen in severe hemophila A or B. Thus the overt
hemorrhagic problems seen in affected individuals would not be a
predicted outcome of normal range variation. Similarly the
extreme high thrombin generation phenotype associated with
AT deficiency is not reproduced by normal range variation,
potentially suggesting a limit to the severity of the thrombotic risk
associated normal range variation. However, such variation does
yield some thrombin generation profiles that are ‘‘abnormal’’, i.e.
the same as phenotypes characterizing individuals with other less
severe composition-based coagulopathies, e.g. that induced by
warfarin anticoagulation. Collectively the data suggest that
unremarkable composition data from a standard laboratory screen
of coagulation factors is not an absolute guarantee of a properly
calibrated response to vascular injury. Composition based analyses
of larger cohorts of apparently healthy as well as hemostatically
challenged individuals, especially those with thrombotic pheno-
types, will be necessary to better establish the boundaries of
‘‘normal’’ thrombin generation.
The sensitivity analysis assessing the effect of pairwise variation
of coagulation factor concentrations identifies the two inhibitors in
the network, TFPI and AT, as potent inducers of overall variation
(Table 2, Table S4). Coordinate expression of extreme high
normal range TFPI and AT concentrations is sufficient to yield
phenotypes similar to individuals characterized by impaired
thrombin generation, i.e. prolonged clot times, and lower max
rate, peak and total thrombin values; this effect is amplified when
fVIII levels are simultaneously at the low end of their normal
range (Table S4) Identifying factors to which the thrombin output
is least sensitive (fVII, fV and fX in this analysis) to their normal
range variation, singly or when assessed paired with other factors,
could reduce the number of input analytes required to capture the
important features of each individual response to injury.
The assessment of the potential of an individual’s blood or
derived plasma fraction to generate thrombin has and continues to
be the primary method of hemostatic monitoring; defects in
thrombin generation are identified by relative assay performance
differences comparing an individual’s outcome to an outcome
typical of apparently healthy individuals. Historically these assays
are designed to monitor clot time as the indicator of hemostatic
competence and are most sensitive to gross differences in com-
position, e.g. severe deficiencies of specific factors [25]. More
recently ‘‘global’’ thrombin assays have provided a more robust
account of the flux of thrombin generation in closed systems after
tissue factor initiation and their applicability to the diagnosis of
coagulopathies is an area of active research [35,36,37,38,39,40,41].
However, as with the clot based assays, those readouts, whether
defined as typical or atypical, do not explain the origins of their
features and as to why one individual appears the same or different
from another. This modeling based approach requires coagulation
factor analyses of each individual’s citrate plasma sample, but yields
a representation of an individual’s coagulation state that is easy to
dissect, based on current understanding of the dynamics reflecting
proteins at their physiologic concentrations and native conforma-
tions. It creates a mechanism-basedrationale foraskingthe question
as to whether individuals can be relatively closer to a hemorrhagic
or thrombotic problem and how composition changes in a subset
factors driven by other disease processes, e.g. inflammatory synd-
romes, might have different hemostatic consequences in different
individuals.
Supporting Information
Figure S1 Sensitivity of a model species (a-thrombin) to
variation in initial factor concentration. Thrombin gener-
ation profiles resulting from varying in eleven intervals the initial
concentrations of TFPI (panel A: 46–171%) or AT (panel B: 88–
171%) across their normal range (Low: dotted, high: dash-dot, and
100%: dashed curves) are shown. The solid bold lines in these
panels represent the ensemble standard deviation associated with
the mean thrombin concentration at each time point. Panel C:
The coefficient of variation (wIIa
g (t)) at each time point is plotted
for TFPI and AT. The time averaged coefficient of variation
values are shown in the parentheses and represent the mean of the
coefficient of variation values across the 20-min simulation.
(PDF)
Table 2. Most potent inducers of alteration in thrombin
parameters: single versus factor pair variation.
Thrombin Parameter Single Factor Factor Pair
Clot Time TFPI (TFPI, AT)
Max Thrombin II (II, AT).(TFPI, II)
Max Rate AT=TFPI$II (TFPI, II)=(TFPI, VIII)
Total Thrombin II.AT (II, AT)
doi:10.1371/journal.pone.0030385.t002
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range for each non-zero factor (g) at selected times.
Coefficient of variation for thrombin (wIIa
g (t)) characterizing
predicted thrombin concentrations is plotted for each of the 8
protein factors at reference times (Figure 1) during the coagulation
process. In panels representing 2.0 & 20.0 min, insets shows
changes in the coefficient of variation that are dramatically smaller
than other time points (10-4). Large bars imply that normal range
variation leads to relatively higher variability in the level of
thrombin at that time point.
(PDF)
Figure S3 Aggregate sensitivity of model species as a
function of normal range variation of each factor (g)a t
selected times. Coefficients of variation for the 15 most sensitive
model species for each of the 8 non-zero protein factors (g)a t
relevant times during the coagulation cascade are presented. Each
species coefficient of variation is represented by a color and its
magnitude by the length. Long bars imply the greatest effects of
normal range variation on the dynamics of the simulation.
(PDF)
Table S1 Ordinary differential equations comprising
the model.
(PDF)
Table S2 Typical initial coagulation factor concentra-
tions and their normal ranges.
(PDF)
Table S3 Factor levels for control, hemophilia &
warfarin groups (Mean ± SD).
(PDF)
Table S4 Hypothetical normal range plasma composi-
tions resulting in extreme thrombin generation pheno-
types. A rank ordering for each of the 6561 simulations for four
metrics is shown with the combination of initial factor concentra-
tions that produced them.
(PDF)
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